GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection.

This study demonstrates that oxysterols drive inflammation in the lung GPR183 and provides the first preclinical evidence for the therapeutic benefit of targeting GPR183 during severe viral respiratory infections.